Hans Carl Hasselbalch

List of Publications by Year
in descending order

264 papers	10,009 citations	47004 47 h-index	46795 89 g-index
268 all docs	268 docs citations	268 times ranked	6979 citing authors

#	Article	IF	Citations
1	Genomic profiling of a randomized trial of interferon-Î± vs hydroxyurea in MPN reveals mutation-specific responses. Blood Advances, 2022, 6, 2107-2119.	5.2	26
2	Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation. EClinicalMedicine, 2022, 43, 101248.	7.1	6
3	Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia, 2022, 36, 1408-1411.	7.2	37
4	Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression. Frontiers in Immunology, 2022, 13, .	4.8	0
5	Coronary artery- and aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms. International Journal of Cardiology, 2022, 364, 112-118.	1.7	5
6	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 2022, 14, .	12.4	10
7	Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms. PLoS ONE, 2022, 17, e0270669.	2.5	6
8	Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: A retrospective cohort study. British Journal of Haematology, 2021, 193, 83-92.	2.5	6
9	Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. Frontiers in Oncology, 2021, 11, 637420.	2.8	29
10	Response to pegylated interferon in a COVIDâ€19â€“positive elderly woman with primary myelofibrosis treated with ruxolitinib. Clinical Case Reports (discontinued), 2021, 9, 2228-2235.	0.5	7
11	The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood, 2021, 137, 2152-2160.	1.4	51
12	Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study. Redox Biology, 2021, 41, 101895.	9.0	8
13	Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care. BMC Cancer, 2021, 21, 691.	2.6	2
14	Response to pegylated interferon in a COVIDâ€19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus. Clinical Case Reports (discontinued), 2021, 9, e04218.	0.5	2
15	COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine and Growth Factor Reviews, 2021, 60, 28-45.	7.2	21
16	Dataâ€driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. European Journal of Haematology, 2021, 107, 624-633.	2.2	6
17	Labor Market Attachment in Patients with Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study. Blood, 2021, 138, 3627-3627.	1.4	0
18	The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients. Blood, 2021, 138, 3589-3589.	1.4	0

#	Article	IF	Citations
19	New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms. HemaSphere, 2021, 5, e645.	2.7	17
20	Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials. Blood, 2021, 138, 3660-3660.	1.4	1
21	Doseâ€dependent mathematical modeling of interferonâ€Î±â€treatment for personalized treatment of myeloproliferative neoplasms. Computational and Systems Oncology, 2021, 1, .	1.5	2
22	Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system. Aging, 2021, 13, 25763-25777.	3.1	6
23	The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera. European Journal of Haematology, 2020, 104, 46-54.	2.2	5
24	Smoking, blood cells and myeloproliferative neoplasms: metaâ€analysis and Mendelian randomization of 2Â·3 million people. British Journal of Haematology, 2020, 189, 323-334.	2.5	27
25	Cytokine Profiling as a Novel Complementary Tool to Predict Prognosis in MPNs?. HemaSphere, 2020, 4, e407.	2.7	8
26	Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study. EClinicalMedicine, 2020, 21, 100280.	7.1	19
27	Ageâ€related prevalence and clinical significance of neutropenia â€isolated or combined with other cytopenias: Real world data from 373â€‰820 primary care individuals. American Journal of Hematology, 2020, 95, 521-528.	4.1	10
28	Increased oxidative stress with substantial dysregulation of genes related to oxidative stress and DNA repair after laparoscopic colon cancer surgery. Surgical Oncology, 2020, 35, 71-78.	1.6	5
29	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Blood Advances, 2020, 4, 3063-3071.	5.2	7
30	Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimerâ€™s disease: evidences and perspectives. Journal of Neuroinflammation, 2020, 17, 248.	7.2	8
31	Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration. EClinicalMedicine, 2020, 26, 100526.	7.1	10
32	Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Cancers, 2020, 12, 573.	3.7	13
33	Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers, 2020, 12, 1763.	3.7	17
34	Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study. EClinicalMedicine, 2020, 21, 100295.	7.1	5
35	Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm. EClinicalMedicine, 2020, 22, 100337.	7.1	2
36	Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Td (C Haematology,the, 2020, 7, e196-e208.	4.6	199

#	Article	IF	Citations
37	Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. Cancer Immunology, Immunotherapy, 2020, 69, 315-324.	4.2	12
38	Ruxolitinib and interferon-Î±2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica, 2020, 105, 2262-2272.	3.5	67
39	Dataâ€driven analysis of JAK2 V617F kinetics during interferonâ€alpha2 treatment of patients with polycythemia vera and related neoplasms. Cancer Medicine, 2020, 9, 2039-2051.	2.8	21
40	Global dynamics of healthy and cancer cells competing in the hematopoietic system. Mathematical Biosciences, 2020, 326, 108372.	1.9	7
41	Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension. Blood, 2020, 136, 33-33.	1.4	11
42	Ropeginterferon Alfaâ€2b: Efficacy and Safety in Different Age Groups. HemaSphere, 2020, 4, e485.	2.7	7
43	Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Clinical Epidemiology, 2019, Volume 11, 23-33.	3.0	18
44	Cancer immune therapy for myeloid malignancies: present and future. Seminars in Immunopathology, 2019, 41, 97-109.	6.1	16
45	Association of the blood eosinophil count with end-organ symptoms. Annals of Medicine and Surgery, 2019, 45, 11-18.	1.1	11
46	Bâ€cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferonâ€Î±2, or combination treatment. European Journal of Haematology, 2019, 103, 351-361.	2.2	6
47	Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood, 2019, 134, 469-479.	1.4	139
48	Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. Experimental Hematology, 2019, 79, 26-34.	0.4	8
49	High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. Blood Cancer Journal, 2019, 9, 8.	6.2	27
50	Neo-antigen specific memory T-cell responses in healthy individuals. OncoImmunology, 2019, 8, e1599640.	4.6	2
51	Smoking and Increased White and Red Blood Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 965-977.	2.4	98
52	Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis. Leukemia and Lymphoma, 2019, 60, 2549-2557.	1.3	5
53	Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?. Haematologica, 2019, 104, 2119-2125.	3.5	10
54	Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms â€“ Impact Of Comorbidity . Clinical Epidemiology, 2019, Volume 11, 955-967.	3.0	34

#	Article	IF	Citations
55	Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?. Annals of Hematology, 2019, 98, 101-109.	1.8	7
56	Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?. Seminars in Immunopathology, 2019, 41, 5-19.	6.1	71
57	JAK2V617F but not CALR mutations confer increased molecular responses to interferon-Î± via JAK1/STAT1 activation. Leukemia, 2019, 33, 995-1010.	7.2	43
58	Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group. European Journal of Haematology, 2019, 102, 235-240.	2.2	21
59	Bridging blood cancers and inflammation: The reduced Cancitis model. Journal of Theoretical Biology, 2019, 465, 90-108.	1.7	11
60	Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. Platelets, 2019, 30, 206-212.	2.3	21
61	Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Blood, 2019, 134, 2978-2978.	1.4	6
62	Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms. European Journal of Haematology, 2018, 100, 550-559.	2.2	17
63	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	7.2	415
64	Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. OncoImmunology, 2018, 7, e1433521.	4.6	30
65	Myeloproliferative Neoplasms in Danish Twins. Acta Haematologica, 2018, 139, 195-198.	1.4	8
66	Whole Blood Gene Expression Profiling in patients undergoing colon cancer surgery identifies differential expression of genes involved in immune surveillance, inflammation and carcinogenesis. Surgical Oncology, 2018, 27, 208-215.	1.6	10
67	Effects of rituximab and dexamethasone on regulatory and proinflammatory Bâ€cell subsets in patients with primary immune thrombocytopenia. European Journal of Haematology, 2018, 100, 45-52.	2.2	12
68	Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes. Leukemia and Lymphoma, 2018, 59, 973-977.	1.3	15
69	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. New England Journal of Medicine, 2018, 379, 1416-1430.	27.0	442
70	Smoking is associated with increased risk of myeloproliferative neoplasms: A general populationâ€based cohort study. Cancer Medicine, 2018, 7, 5796-5802.	2.8	31
71	Safety and efficacy of combination therapy of interferonâ€Î±2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Medicine, 2018, 7, 3571-3581.	2.8	38
72	Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. OncoImmunology, 2018, 7, e1468957.	4.6	15

#	Article	IF	Citations
73	The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms-An explorative study. European Journal of Cancer Care, 2018, 27, e12865.	1.5	8
74	Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation. Blood, 2018, 132, 4326-4326.	1.4	3
75	Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Review of Hematology, 2017, 10, 393-404.	2.2	25
76	A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera. British Journal of Haematology, 2017, 177, 800-805.	2.5	9
77	The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms. Leukemia and Lymphoma, 2017, 58, 1914-1921.	1.3	17
78	Molecular profiling as a novel tool to predict response to interferonâ€Î±2 in MPNs: The proof of concept in early myelofibrosis. Cancer, 2017, 123, 2600-2603.	4.1	4
79	Anemia is present years before myelodysplastic syndrome diagnosis: Results from the preâ€diagnostic period. American Journal of Hematology, 2017, 92, E130-E132.	4.1	5
80	Nonâ€invasive imaging of retinal blood flow in myeloproliferative neoplasms. Acta Ophthalmologica, 2017, 95, 146-152.	1.1	21
81	Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations. Scientific Reports, 2017, 7, 6774.	3.3	16
82	The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy. OncoImmunology, 2017, 6, e1358334.	4.6	10
83	Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms. JAMA Ophthalmology, 2017, 135, 835.	2.5	29
84	Second malignancies in hydroxyurea and interferonâ€treated Philadelphiaâ€negative myeloproliferative neoplasms. European Journal of Haematology, 2017, 98, 75-84.	2.2	33
85	Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP). Platelets, 2017, 28, 478-483.	2.3	10
86	A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents. Clinical Epidemiology, 2017, Volume 9, 141-150.	3.0	8
87	Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. PLoS ONE, 2017, 12, e0183620.	2.5	51
88	The Danish National Chronic Myeloid Neoplasia Registry. Clinical Epidemiology, 2016, Volume 8, 567-572.	3.0	11
89	Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment. PLoS ONE, 2016, 11, e0165336.	2.5	38
90	Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study. Journal of Internal Medicine, 2016, 279, 566-575.	6.0	31

#	Article	IF	Citations
91	Smoking and philadelphiaâ€negative chronic myeloproliferative neoplasms. European Journal of Haematology, 2016, 97, 63-69.	2.2	36
92	Increased iron stores prolong the <scp>QT</scp> interval â€“ a general population study including 20Â261 individuals and metaâ€analysis of thalassaemia major. British Journal of Haematology, 2016, 174, 776-785.	2.5	8
93	Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?. Leukemia and Lymphoma, 2016, 57, 1793-1799.	1.3	19
94	A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate. Leukemia Research Reports, 2016, 6, 20-23.	0.4	8
95	A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms. Quality of Life Research, 2016, 25, 835-846.	3.1	15
96	Interferonâ€Î± induces marked alterations in circulating regulatory T cells, <scp>NK</scp> cell subsets, and dendritic cells in patients with <scp>JAK</scp>2V617Fâ€positive essential thrombocythemia and polycythemia vera. European Journal of Haematology, 2016, 97, 83-92.	2.2	30
97	Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia Research, 2016, 41, 27-35.	0.8	24
98	Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. Hematology, 2016, 21, 387-391.	1.5	14
99	Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. Leukemia and Lymphoma, 2016, 57, 125-128.	1.3	16
100	Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leukemia and Lymphoma, 2016, 57, 348-354.	1.3	40
101	Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients. Blood, 2016, 128, 475-475.	1.4	24
102	A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis. PLoS ONE, 2016, 11, e0161570.	2.5	6
103	Effects of Rituximab and Dexamethasone on Regulatory and Pro-Inflammatory B-Cell Subsets in Patients with Primary Immune Thrombocytopenia. Blood, 2016, 128, 1378-1378.	1.4	0
104	The impact of ruxolitinib treatment on inflammationâ€mediated comorbidities in myelofibrosis and related neoplasms. Clinical Case Reports (discontinued), 2015, 3, 499-503.	0.5	14
105	<scp>WHO</scp> classification 2008 of myeloproliferative neoplasms: a workshop learning effect â€“ the Danish experience. Apmis, 2015, 123, 787-792.	2.0	4
106	Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. Oncotarget, 2015, 6, 40588-40597.	1.8	14
107	MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators of Inflammation, 2015, 2015, 1-16.	3.0	155
108	The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. Mediators of Inflammation, 2015, 2015, 1-11.	3.0	63

#	Article	IF	Citations
109	Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art. Mediators of Inflammation, 2015, 2015, 1-3.	3.0	14
110	Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?. Expert Review of Hematology, 2015, 8, 439-445.	2.2	13
111	<scp>A</scp>ssociation of the blood eosinophil count with hematological malignancies and mortality. American Journal of Hematology, 2015, 90, 225-229.	4.1	20
112	Expansion of circulating CD56^{bright} natural killer cells in patients with JAK2â€positive chronic myeloproliferative neoplasms during treatment with interferonâ€Î±. European Journal of Haematology, 2015, 94, 227-234.	2.2	45
113	Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study. Lancet Haematology,the, 2015, 2, e289-e296.	4.6	19
114	High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. European Journal of Internal Medicine, 2015, 26, 344-347.	2.2	49
115	Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer?. Gynecologic Oncology, 2015, 139, 312-318.	1.4	10
116	Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis. European Journal of Haematology, 2015, 94, 96-98.	2.2	18
117	Smoking as a contributing factor for development of polycythemia vera and related neoplasms. Leukemia Research, 2015, 39, 1137-1145.	0.8	36
118	No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study. Blood, 2015, 126, 5177-5177.	1.4	1
119	Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study. Blood, 2015, 126, 824-824.	1.4	14
120	Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. Blood, 2015, 126, 825-825.	1.4	24
121	Are Chronic Myeloproliferative Neoplasms Associated with Age-Related Macular Degeneration?. Blood, 2015, 126, 4444-4444.	1.4	0
122	A Heterogeneous Response Pattern to Interferon-alpha2 with Induction of a Significant Decrease in the Calreticulin Mutant Allele Burden in a Subset of Patients with Essential Thrombocythemia and Primary Myelofibrosis. Blood, 2015, 126, 4057-4057.	1.4	0
123	The Impact of Interferon-alpha2 on HLA-Genes in Patients with Polycythemia Vera and Related Neoplasms. Blood, 2015, 126, 4097-4097.	1.4	0
124	Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression. PLoS ONE, 2014, 9, e112786.	2.5	59
125	Transcriptional Profiling of Whole Blood Identifies a Unique 5-Gene Signature for Myelofibrosis and Imminent Myelofibrosis Transformation. PLoS ONE, 2014, 9, e85567.	2.5	13
126	The Copenhagen Primary Care Differential Count (CopDiff) database. Clinical Epidemiology, 2014, 6, 199.	3.0	16

#	Article	IF	Citations
127	Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Review of Hematology, 2014, 7, 203-216.	2.2	40
128	Eosinophilia in routine blood samples as a biomarker for solid tumor development â€“ A study based on The Copenhagen Primary Care Differential Count (CopDiff) Database. Acta OncolÃ³gica, 2014, 53, 1245-1250.	1.8	9
129	A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. Haematologica, 2014, 99, e5-e7.	3.5	22
130	Circulating <scp>YKL</scp>â€40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. European Journal of Haematology, 2014, 93, 224-228.	2.2	21
131	The plateletâ€“cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?. Leukemia Research, 2014, 38, 1230-1236.	0.8	26
132	Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia Research, 2014, 38, 490-495.	0.8	38
133	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research, 2014, 38, 816-821.	0.8	12
134	A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?. Leukemia Research, 2014, 38, 263-266.	0.8	23
135	Risk of Lymphoma and Solid Cancer among Patients with Rheumatoid Arthritis in a Primary Care Setting. PLoS ONE, 2014, 9, e99388.	2.5	15
136	Prediagnostic Thrombocytosis Increases the Risk of Advanced Gynecological Cancer and Increases Mortality Independently of Cancer Stage â€“ a Population-Based Study. Blood, 2014, 124, 2791-2791.	1.4	0
137	DNA Methylation Profiling of Sorted Cells from Myelofibrosis Patients reveals Aberrant Epigenetic Regulation of Immune Pathways and identifies Early MPN Driver Genes. Blood, 2014, 124, 4576-4576.	1.4	0
138	A phase II study of vorinostat (<scp>MK</scp>â€0683) in patients with polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 2013, 162, 498-508.	2.5	65
139	Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leukemia Research Reports, 2013, 2, 1-3.	0.4	30
140	Myeloproliferative neoplasms in five multiple sclerosis patients. Leukemia Research Reports, 2013, 2, 61-63.	0.4	4
141	A phase <scp>III</scp> randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology, 2013, 163, 393-399.	2.5	135
142	World Health Organizationâ€defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlationsâ€"The Danish experience. American Journal of Hematology, 2013, 88, 1012-1016.	4.1	48
143	Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leukemia Research, 2013, 37, 1041-1045.	0.8	84
144	Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Review of Hematology, 2013, 6, 49-58.	2.2	96

#	Article	IF	Citations
145	Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?. Leukemia Research, 2013, 37, 214-220.	0.8	198
146	The role of cytokines in the initiation and progression of myelofibrosis. Cytokine and Growth Factor Reviews, 2013, 24, 133-145.	7.2	128
147	Activated Platelets Enhance IL-10 Secretion and Reduce TNF-Î± Secretion by Monocytes. Journal of Immunology, 2013, 191, 4059-4067.	0.8	104
148	Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leukemia and Lymphoma, 2013, 54, 2269-2273.	1.3	40
149	Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death. American Journal of Hematology, 2013, 88, 843-847.	4.1	33
150	Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood, 2013, 121, 1976-1981.	1.4	146
151	Rapid Clearance Of JAK2 V617F Allele Burden In Patient With Advanced Polycythemia Vera (PV) During Combination Therapy With Ruxolitinib and Peg-Interferon Alpha-2a. Blood, 2013, 122, 5241-5241.	1.4	5
152	Polycythemia-Inducing Mutations In The Erythropoietin Receptor (EPOR): Mechanism and Function Elucidated By EGFRâ€“ EPOR Chimeras. Blood, 2013, 122, 2174-2174.	1.4	0
153	Risks of Eosinophil-Related End-Organ Damage, Hematological Malignancies and Death Are Significantly Increased Even below Consensus Threshold Criteria for Blood Eosinophilia. Blood, 2013, 122, 2831-2831.	1.4	1
154	Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 2012, 53, 123-129.	1.3	50
155	Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?. Blood, 2012, 119, 3219-3225.	1.4	255
156	Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Experimental Hematology, 2012, 40, 771-780.e19.	0.4	55
157	Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance. Leukemia Research, 2012, 36, 1387-1392.	0.8	60
158	Response: cancer risk in chronic myeloproliferative neoplasms. Blood, 2012, 119, 3862-3863.	1.4	1
159	Thrombopoietin-receptor agonists in haematological disorders: The Danish experience. Platelets, 2012, 23, 423-429.	2.3	23
160	A novel immunohistochemical sequential multiâ€labelling and erasing technique enables epitope characterization of bone marrow pericytes in primary myelofibrosis. Histopathology, 2012, 60, 554-560.	2.9	6
161	Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms. Leukemia Research, 2012, 36, 485-487.	0.8	6
162	A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood, 2012, 120, 803-803.	1.4	4

#	Article	IF	Citations
163	A Highly Sensitive Quantitative Real-Time PCR Assay for Determination of Mutant JAK2 Exon 12 Allele Burden. PLoS ONE, 2012, 7, e33100.	2.5	18
164	An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).. Blood, 2012, 120, 2844-2844.	1.4	3
165	Hydroxycarbamide: a userâ€™s guide for chronic myeloproliferative disorders. Expert Review of Anticancer Therapy, 2011, 11, 403-414.	2.4	72
166	Editorial [Hot Topic: Interferon Alpha2 in the Treatment of Hematological Malignancies. Status and Perspectives (Guest Editor: Hans Carl Hasselbalch)]. Current Drug Targets, 2011, 12, 387-391.	2.1	2
167	Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-Î±. Blood, 2011, 118, 2170-2173.	1.4	59
168	Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood, 2011, 118, 6515-6520.	1.4	149
169	Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. British Journal of Haematology, 2011, 155, 248-255.	2.5	34
170	The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis. Apmis, 2011, 119, 498-504.	2.0	13
171	Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. European Journal of Haematology, 2011, 87, 54-60.	2.2	53
172	High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis. Leukemia Research, 2011, 35, 1330-1334.	0.8	13
173	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	1.6	724
174	FLT3-Mediated p38â€"MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis. Cancer Research, 2011, 71, 2901-2915.	0.9	46
175	Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Journal of Clinical Oncology, 2011, 29, e564-e565.	1.6	20
176	A new era for IFN-Î± in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Review of Hematology, 2011, 4, 637-655.	2.2	66
177	Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives. Current Drug Targets, 2011, 12, 392-419.	2.1	34
178	The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,. Blood, 2011, 118, 3834-3834.	1.4	0
179	Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica, 2010, 95, 2153-2156.	3.5	19
180	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010, 148, 961-963.	2.5	144

#	Article	IF	Citations
181	Increased Expression of Proteasome-Related Genes In Patients with Primary Myelofibrosis. Blood, 2010, 116, 4117-4117.	1.4	5
182	The Importance of a Bone Marrow Biopsy to Distinguish Primary Immune Thrombocytopenia From Indolent Haematological Malignancies. Blood, 2010, 116, 4676-4676.	1.4	0
183	Enhanced Gene Expression of EZH2 In Patients with Primary Myelofibrosis. Blood, 2010, 116, 4118-4118.	1.4	0
184	Gene Expression Profiling with Principal Component Analysis Depicts the Biological Continuum From Essential Thrombocythemia Over Polycythemia Vera to Myelofibrosis. Blood, 2010, 116, 4115-4115.	1.4	0
185	Increased Gene Expression of Histone Deacetylases In Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Blood, 2010, 116, 4119-4119.	1.4	1
186	High Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule(CEACAM) 6 In Primary Myelofibrosis. Blood, 2010, 116, 4116-4116.	1.4	10
187	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 2009, 113, 4829-4833.	1.4	229
188	Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology, 2009, 14, 331-334.	1.5	76
189	Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology, 2009, 14, 11-15.	1.5	22
190	Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer. Leukemia Research, 2009, 33, 11-18.	0.8	40
191	FLT3-Mediated MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis.. Blood, 2009, 114, 963-963.	1.4	1
192	Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood, 2008, 112, 3026-3035.	1.4	119
193	High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Hematology, 2008, 13, 71-76.	1.5	16
194	MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood, 2008, 112, 141-149.	1.4	371
195	Angiogenesis in pulmonary hypertension with myelofibrosis. Haematologica, 2008, 93, 945-946.	3.5	16
196	Minimal Residual Disease and Normalization of the Bone Marrow after Long-Term Treatment with Alpha-Interferon2b in Polycythemia Vera. A Report on Seven Patients in Sustained Complete Hematological Remission with Major Molecular Responses.. Blood, 2008, 112, 1744-1744.	1.4	1
197	Limited Efficacy of Hydroxyurea in Lowering of the JAK2 V617F Allele Burden.. Blood, 2008, 112, 1750-1750.	1.4	14
198	B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Gravesâ€™ Disease: A Controlled Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1769-1772.	3.6	133

#	Article	IF	Citations
199	Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. Haematologica, 2007, 92, 597-604.	3.5	31
200	The Mevalonate Pathway as a Therapeutic Target in the Ph-Negative Chronic Myeloproliferative Disorders. Current Drug Targets, 2007, 8, 247-256.	2.1	6
201	Editorial [Hot Topic: Highlights on Important Signaling Pathways as Drug Targets in Hematological Malignancies (Guest Editors: H. Serve and H.C. Hasselbalch)]. Current Drug Targets, 2007, 8, 203-203.	2.1	0
202	B-cell depletion with rituximab in the treatment of autoimmune diseases. Expert Opinion on Biological Therapy, 2007, 7, 1061-1078.	3.1	46
203	The JAK2 V617F mutation involves Bâ€•and Tâ€lymphocyte lineages in a subgroup of patients with Philadelphiaâ€chromosome negative chronic myeloproliferative disorders. British Journal of Haematology, 2007, 136, 745-751.	2.5	148
204	Extreme neutrophil granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage.. Apmis, 2007, 115, 778-783.	2.0	5
205	Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia. Apmis, 2007, 115, 1267-1273.	2.0	3
206	A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis. Cancer Genetics and Cytogenetics, 2007, 172, 107-112.	1.0	12
207	The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis â€" impact on disease phenotype. European Journal of Haematology, 2007, 79, 508-515.	2.2	130
208	Darbepoetin Alfa for the Treatment of Anemia in Patients with Myelofibrosis with Myeloid Metaplasia (MMM). Results from a Danish Multicenter Study.. Blood, 2007, 110, 4641-4641.	1.4	0
209	The rationale for B lymphocyte depletion in Gravesâ€™ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. European Journal of Endocrinology, 2006, 154, 623-632.	3.7	71
210	V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 2006, 107, 2098-2100.	1.4	194
211	Statins in the treatment of polycythaemia vera and allied disorders: An antithrombotic and cytoreductive potential?. Leukemia Research, 2006, 30, 1217-1225.	0.8	34
212	A phase II trial of pegylated interferon Î±-2b therapy for polycythemia vera and essential thrombocythemia. Cancer, 2006, 106, 2397-2405.	4.1	104
213	Treatment-Resistant Severe, Active Graves' Ophthalmopathy Successfully Treated with B Lymphocyte Depletion. Thyroid, 2006, 16, 709-710.	4.5	110
214	Quantitative PCR Assessment of JAK2 Mutational Status in Philadelphia-Chromosome Negative Chronic Myeloproliferative Disorders - The JAK2 V617F Mutation Is an Event in an Early Stem Cell and the Clonal Involvement of Different Haematopoietic Cells Varies between Individual Patients.. Blood, 2006, 108, 3602-3602.	1.4	0
215	Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood, 2005, 106, 2849-2853.	1.4	75
216	Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. American Journal of Hematology, 2005, 78, 275-280.	4.1	121

#	Article	IF	Citations
217	Glivec/STI571 Treatment Stimulates Megakaryopoiesis and Normalizes PDGF Receptor beta Kinase Expression in Thrombocytopenic Patients with Myeloid Metaplasia with Myelofibrosis.. Blood, 2005, 106, 2599-2599.	1.4	3
218	Imatinib Mesylate in Polycythemia Vera. A Heterogeneous Response Pattern but a Consistent Reduction in Phlebotomy Requirements.. Blood, 2004, 104, 4747-4747.	1.4	3
219	Elevated plasma levels of TIMPâ€1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders. European Journal of Haematology, 2003, 71, 377-384.	2.2	17
220	Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasmaâ€soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. European Journal of Haematology, 2003, 71, 276-282.	2.2	9
221	Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. American Journal of Hematology, 2003, 74, 26-31.	4.1	61
222	Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. American Journal of Hematology, 2003, 74, 238-242.	4.1	35
223	B-cell depletion with rituximabâ€"a targeted therapy for Gravesâ€™ disease and autoimmune thyroiditis. Immunology Letters, 2003, 88, 85-86.	2.5	37
224	Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera. European Journal of Haematology, 2002, 69, 43-49.	2.2	11
225	Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. American Journal of Hematology, 2002, 69, 185-191.	4.1	36
226	Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin. American Journal of Hematology, 2002, 70, 92-99.	4.1	27
227	A possible role for STI571 in the treatment of idiopathic myelofibrosis. American Journal of Hematology, 2001, 68, 63-64.	4.1	3
228	Increased circulating plateletâ€"leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. European Journal of Haematology, 2001, 66, 143-151.	2.2	115
229	Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopeniaâ€"and neutropenia. European Journal of Haematology, 2001, 66, 408-411.	2.2	41
230	Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. British Journal of Haematology, 2000, 110, 116-124.	2.5	100
231	Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. European Journal of Haematology, 2000, 65, 132-139.	2.2	118
232	Fatal virus-associated hemophagocytic syndrome associated with coexistent chronic active hepatitis B and acute hepatitis C virus infection. , 1999, 61, 135-138.		11
233	Serum hyaluronan is increased in malignant lymphoma. American Journal of Hematology, 1995, 50, 231-233.	4.1	18
234	Serum laminin P1 in idiopathic myelofibrosis and related diseases. Leukemia Research, 1994, 18, 623-628.	0.8	5

#	Article	IF	Citations
235	Idiopathic myelofibrosis â€" an update with particular reference to clinical aspects and prognosis. International Journal of Clinical and Laboratory Research, 1993, 23, 124-138.	1.0	32
236	Evidence for an association between hairy cell leukemia and renal cell and colorectal carcinoma. Cancer, 1992, 70, 2087-2090.	4.1	23
237	Aberrations of chromosome 6 in 193 newly diagnosed untreated cases of chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 1991, 53, 35-43.	1.0	16
238	Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases.. Apmis, 1991, 99, 171-178.	2.0	33
239	Demonstrated Benefit of Continuous Interferon-Alpha-2b Therapy in Hairy Cell Leukemia. A Two-Year Follow-Up. Leukemia and Lymphoma, 1991, 5, 23-31.	1.3	5
240	A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis. European Journal of Haematology, 1991, 46, 285-289.	2.2	26
241	On the pathogenesis of angiogenesis in idiopathic myelofibrosis. American Journal of Hematology, 1990, 33, 151-151.	4.1	9
242	Idiopathic myelofibrosis: A clinical study of 80 patients. American Journal of Hematology, 1990, 34, 291-300.	4.1	79
243	Prognostic factors in idiopathic myelofibrosis: A simple scoring system with prognostic significance. European Journal of Haematology, 1990, 44, 172-178.	2.2	27
244	Idiopathic myelofibrosis: A review. European Journal of Haematology, 1990, 45, 65-72.	2.2	26
245	Whole blood assay for NK activity in splenectomized and non-splenectomized hairy cell leukemia patients during IFN-Î±-2b treatment. Leukemia Research, 1989, 13, 451-456.	0.8	5
246	Immunological recovery and dose evaluation in IFNâ€Î± treatment of hairy cell leukemia: Analysis of leukocyte differentiation antigens, NK and 2â€˜,5â€™â€oligoadenylate synthetase activity. European Journal of Haematology, 1989, 42, 50-59.	2.2	11
247	INTERFERON IN MYELOFIBROSIS. Lancet, The, 1988, 331, 355.	13.7	29
248	Alcohol Intolerance in the Hypereosinophilic Syndrome. Alcoholism: Clinical and Experimental Research, 1988, 12, 147-148.	2.4	5
249	Recombinant interferonâ€alphaâ€2b treatment of hairyâ€cell leukaemia: Experience with a lowâ€dose schedule. European Journal of Haematology, 1988, 41, 438-444.	2.2	17
250	FURTHER EVIDENCE OF THE EFFICACY OF INTERFERON FOR Tâ€CELL HAIRY CELL LEUKAEMIA: To the Editor:. European Journal of Haematology, 1988, 40, 188-189.	2.2	3
251	A distinct subtype of idiopathic myelofibrosis with bone marrow features mimicking hairy cell leukemia: Evidence of an autoimmune pathogenesis. American Journal of Hematology, 1987, 25, 225-229.	4.1	23
252	Urinary hydroxyproline excretion in the myelofibrosisâ€osteomyelosclerosis syndrome and related diseases. European Journal of Haematology, 1987, 39, 447-451.	2.2	2

#	Article	IF	Citations
253	Plasma fibronectin in idiopathic myelofibrosis and related chronic myeloproliferative disorders. Scandinavian Journal of Clinical and Laboratory Investigation, 1987, 47, 429-433.	1.2	4
254	Nonâ€Hodgkin malignant lymphomas and Hodgkin's disease in firstâ€degree relatives. Scandinavian Journal of Haematology, 1986, 36, 398-401.	0.0	11
255	Circulating immune complexes in myelofibrosis. Scandinavian Journal of Haematology, 1985, 34, 177-180.	0.0	19
256	Pericardial haematopoiesis with tamponade in myelofibrosis. Scandinavian Journal of Haematology, 1985, 34, 270-273.	0.0	8
257	Serum procollagen III peptide in chronic myeloproliferative disorders. Scandinavian Journal of Haematology, 1985, 35, 550-557.	0.0	18
258	Urinary Free Cortisol During Pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 1984, 63, 253-256.	2.8	6
259	Spongy Lymphoid Myelofibrosis as a Predictor of Hairy Cell Leukaemia or a Variant of Hairy Cell Leukaemia without Hairy Cells?. Scandinavian Journal of Haematology, 1984, 32, 135-144.	0.0	10
260	Redâ€Cell Sensitization in Myelofibrosis. Scandinavian Journal of Haematology, 1984, 32, 179-182.	0.0	5
261	Hairyâ€cell leukaemia simulating connective tissue disease. Scandinavian Journal of Haematology, 1984, 32, 457-460.	0.0	3
262	Plateletâ€associated IgG and IgM in myelofibrosis. Scandinavian Journal of Haematology, 1984, 32, 488-492.	0.0	10
263	Transition of Myelofibrosis to Polycythaemia Vera. Scandinavian Journal of Haematology, 1983, 30, 161-166.	0.0	13
264	Serum Prolactin and Thyrotropin Responses to Thyrotropinâ€Releasing Hormone in Men with Alcoholic Cirrhosis. Acta Medica Scandinavica, 1981, 209, 37-40.	0.0	20